This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....